Опубликована: Дек. 27, 2024
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 1250 - 1250
Опубликована: Янв. 19, 2024
Schizophrenia (SCZ) is an articulated psychiatric syndrome characterized by a combination of genetic, epigenetic, and environmental factors. Our intention to present pathogenetic model combining SCZ alterations the main cellular actors blood-brain barrier (BBB): endothelial cells (ECs), pericytes, astrocytes. The homeostasis BBB preserved neurovascular unit which constituted ECs, astrocytes microglia, neurons, extracellular matrix. role strictly linked its ability preserve biochemical integrity brain parenchyma integrity. In SCZ, there increased permeability, demonstrated elevated levels albumin immunoglobulins in cerebrospinal fluid, this result intrinsic impairment. Increased permeability would lead enhanced concentrations neurotoxic neuroactive molecules brain. involvement reverberates consequences on BBB, together with impact selectivity represented EC pericyte damage occurring psychotic picture. Understanding strict interaction between ECs astrocytes, consequent cognition, diriment not only for comprehension neurotransmitter dyshomeostasis but also focusing other potential therapeutic targets.
Язык: Английский
Процитировано
10
Brain Sciences, Год журнала: 2023, Номер 13(8), С. 1193 - 1193
Опубликована: Авг. 11, 2023
Schizophrenia is a chronic neuropsychiatric syndrome that significantly impacts daily function and quality of life. All the available guidelines suggest combined treatment approach with pharmacologic agents psychological interventions. However, one in three patients non-responder, effect on negative cognitive symptoms limited, many drug-related adverse effects complicate clinical management. As result, discovering novel drugs for schizophrenia presents significant challenge psychopharmacology. This selective review literature aims to outline current knowledge aetiopathogenesis present recently approved newly discovered pharmacological substances treating schizophrenia. We discuss ten drugs, which have been by FDA (Olanzapine/Samidorphan, Lumateperone, Pimavanserin). The rest are under trial investigation (Brilaroxazine, Xanomeline/Trospium, Emraclidine, Ulotaront, Sodium Benzoate, Luvadaxistat, Iclepertin). additional basic research required not only improve our understanding neurobiology potential targets schizophrenia, but also establish more effective therapeutical interventions syndrome, including attenuation avoiding dopamine blockade-related effects.
Язык: Английский
Процитировано
18
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2024, Номер 133, С. 111010 - 111010
Опубликована: Апрель 18, 2024
Язык: Английский
Процитировано
4
Biomolecules, Год журнала: 2024, Номер 14(8), С. 906 - 906
Опубликована: Июль 25, 2024
Schizophrenia is a frequently debilitating and complex mental disorder affecting approximately 1% of the global population, characterized by symptoms such as hallucinations, delusions, disorganized thoughts behaviors, cognitive dysfunction, negative symptoms. Traditional treatment has centered on postsynaptic dopamine antagonists, commonly known antipsychotic drugs, which aim to alleviate improve functioning quality life. Despite availability these medications, significant challenges remain in schizophrenia therapeutics, including incomplete symptom relief, resistance, medication side effects. This opinion article explores advancements treatment, emphasizing molecular mechanisms, novel drug targets, innovative delivery methods. One promising approach strategies that target neural networks circuits rather than single neurotransmitters, acknowledging complexity brain region interconnections involved schizophrenia. Another development biased agonists, selectively activate specific signaling pathways downstream receptors, offering potential for more precise pharmacological interventions with fewer The concept polypharmacy, where targets multiple pathways, exemplified KarXT, combining xanomeline trospium address both psychosis dysfunction. represents comprehensive strategy potentially improving outcomes patients. In conclusion, advancing understanding exploring therapeutic hold promise addressing unmet needs aiming effective tailored interventions. Future research should focus approaches achieve better clinical functional level life individuals
Язык: Английский
Процитировано
4
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
2
European Archives of Psychiatry and Clinical Neuroscience, Год журнала: 2023, Номер 274(5), С. 1125 - 1135
Опубликована: Дек. 10, 2023
Язык: Английский
Процитировано
4
Pharmacology Biochemistry and Behavior, Год журнала: 2024, Номер 243, С. 173821 - 173821
Опубликована: Июль 11, 2024
Язык: Английский
Процитировано
1
Frontiers in Psychiatry, Год журнала: 2024, Номер 15
Опубликована: Сен. 25, 2024
Schizophrenia is a persistent incurable mental disorder and characterized by the manifestation of negative emotions behaviors with anxiety depression, fear insecurity, self-harm social withdrawal. The intricate molecular mechanisms underlying this phenomenon remain largely elusive. Accumulating evidence points towards gut microbiota exerting an influence on brain function via gut-brain axis, potentially contributing to development schizophrenia. Therefore, objective study delineate microbial composition metabolic profile fecal samples from individuals
Язык: Английский
Процитировано
1
Опубликована: Июль 4, 2023
Schizophrenia is a chronic neuropsychiatric syndrome with significant impact on daily function and quality of life. All available guidelines suggest combined treatment approach pharmacologic agents psychological interventions. However, one in three patients non-responder, the effect negative cognitive symptoms limited, many drug-related adverse effects complicate clinical management. As result, discovering novel drugs for schizophrenia presents challenge psychopharmacology. This narrative review literature aims to present recently approved newly discovered pharmacological substances as well their suggested mechanism action. We discuss seven drugs, which have been by FDA (Olanzapine/Samidorphan, Lumateperone, Pimavanserin). The rest are under trial investigation (Ulotaront, CVL-231, Xanomeline/Trospium, Brilaroxazine). Additional basic research is, however, required not only improve our understanding neurobiology potential targets but also establish modern more effective therapeutical interventions friendlier side-effect profiles.
Язык: Английский
Процитировано
2
Опубликована: Дек. 27, 2024
Язык: Английский
Процитировано
0